Mirati Therapeutics

Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Mirati Therapeutics reports successful KRAZATI launch amidst financial challenges

Mirati Therapeutics had a transformative year with the successful launch of KRAZATI for KRAS G12C mutated lung cancer.
Despite a net loss in Q4 2022, the company ended the year with a strong cash position and positive market feedback.
Challenges include financial losses, maximizing target inhibition with PRMT5 inhibitors, and regulatory hurdles for Phase 3 trials.
Opportunities lie in collaborations, combination therapies, Phase 3 trials, and advancing pipeline products for future growth.

Mirati Therapeutics reports strong Q1 performance and advances pipeline

Mirati Therapeutics showcased a strong financial performance in Q1 2023, driven by the successful launch of KRAZATI and progress in clinical studies for MRTX1133. The company's commitment to advancing its pipeline and addressing inquiries from analysts reflects a strategic focus on innovation and stakeholder engagement. Despite facing challenges such as a significant net loss, Mirati remains well-positioned with a robust cash position and promising growth opportunities.

Mirati Therapeutics reports strong Q2 performance and navigates strategic challenges

Mirati Therapeutics showcased strong commercial performance, promising clinical data, and proactive financial management strategies in its Q2 2023 Earnings Call.
While facing challenges in market positioning, trial complexities, and operational management, the company remains well-positioned to capitalize on opportunities in advancing its pipeline and optimizing financial performance.
Analysts' inquiries highlighted key areas of interest and concern, signaling the importance of strategic decision-making, regulatory navigation, and competitive positioning for Mirati's future success.
Overall, Mirati's focus on innovation, patient outcomes, and financial sustainability underscores its commitment to driving therapeutic advancements, addressing unmet medical needs, and delivering long-term value to stakeholders.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Mirati Therapeutics Inc is a Biotechnology company located in 9363 Towne Centre Dr, San Diego, CA, United States.

NEW YORK, July 6, 2020 /PRNewswire/ --Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Mirati Therapeutics, Inc. ("Mirati" or the "Company") (NASDAQ: MRTX). Investors who purchased Mirati securities are encouraged to...

MRTX Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Mirati Therapeutics, Inc. and Encourages Investors to Contact the Firm

Mirati (MRTX) reported earnings 30 days ago. What's next for the stock?

Mirati (MRTX) Up 4.1% Since Last Earnings Report: Can It Continue?

SAN DIEGO, June 5, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will participate in the upcoming 41st Annual Goldman Sachs Global Healthcare Conference on Thursday, June 11, 2020. Charles M. Baum, M.D., Ph.D., President and...

Mirati Therapeutics to Present at 41st Annual Goldman Sachs Global Healthcare Conference

SAN DIEGO, May 18, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that Joseph Leveque, M.D. has been named Chief Medical Officer effective May 18, 2020. Isan Chen, M.D., will step down as Chief Medical and...

Mirati Therapeutics Appoints Joseph A. Leveque, M.D.

SAN DIEGO, May 15, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced it will present preclinical data on the Company's pipeline of novel therapeutics in three presentations at the American Association for Cancer...

Mirati Therapeutics To Present Preclinical Data From Investigational Pipeline Of Novel Therapeutics At 2020 American Association For Cancer Research Virtual Annual Meeting II

Mirati (MRTX) delivered earnings and revenue surprises of -22.42% and -58.92%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Mirati (MRTX) Reports Q1 Loss, Lags Revenue Estimates

Mirati Therapeutics, Inc.: Cracking KRAS Is Harder Than It Looks

Mirati Therapeutics Inc (NASDAQ: MRTX) shares were seeing weakness Tuesday after short seller Kerrisdale Capital released a bleak report concerning its two investigational assets.

Mirati Dives As Short Seller Says Key Pipeline Assets Doomed

Amgen

Amneal Pharmaceuticals

Viking Therapeutics

Verastem

Healthcare bargain hunters can find good values in quality low-priced stocks.

Top Drug Stocks Under $5

Mirati (MRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Mirati (MRTX) Q4 Earnings Expected to Decline

Revolution Medicines

The share price of a clinical-stage oncology company that went public just last week has climbed more than 70% on hopes that it can develop drugs to transform the way cancer is treated.

Revolution Medicines Joins Amgen and Mirati in Quest for New Type of Cancer Drugs

Results from a combination study breathed life into the company's sitravatinib program.

Here's Why Mirati Therapeutics Jumped 28% in December

ANI Pharma

Immunomedics

PTC Therapeutics

Here we discuss some biotech stocks, which are up this year so far but might not be good additions to your portfolio.

4 Drug/Biotech Outperformers That May Lose Steam in 2020

Investors need to pay close attention to Mirati (MRTX) stock based on the movements in the options market lately.

Options Traders Expect Huge Moves in Mirati (MRTX) Stock

Mirati Therapeutics: A Classic Philip Fisher Growth Stock

Iovance Biotherapeutics

Personalis Inc

MIrati Therapeutics, Iovance Biotherapeutics, and Personalis are all using genetic knowledge to help find cures for cancer.

3  Cancer Treatment Stocks to Buy Right Now

Both biotechs are developing revolutionary new cancer drugs, but which stock is better for your portfolio right now?

Better Buy: Mirati Therapeutics vs. Amgen

It’s looking competitive in one cancer drug class.

Can This Tiny Biotech Take Down Amgen?

This time, its own clinical trial is pushing the biotech higher.

Here's Why Mirati Therapeutics Stock Is on the Move Again Today

An experimental drug from Mirati Therapeutics that targets a specific genetic mutation significantly reduced tumor size in 40% of patients with advanced lung and colorectal cancer so far evaluated in a small, early-stage trial, researchers said on Monday.

Mirati drug shrinks tumors in some cancer patients in early-stage trial

This stock could soar at the end of the month, but is it worth the risk?

Is Mirati Therapeutics a Good Stock to Buy Now?

Mirati Therapeutics Inc (NASDAQ: MRTX), a thinly traded, smid-cap oncology biotech, is on investors' radars ahead of upcoming conference presentations and data readouts.

Biotech Stock On The Radar: Assessing Mirati's Oncology Franchise With An Eye On Multiple Readouts

Autolus Therapeutics

Nektar Therapeutics

Due to the explosion in immuno-oncology in recent years, what was once a small scientific meeting near the end of the year has become a go-to event for drug developers.

3 Companies To Watch For At November’s Society for Immunotherapy of Cancer Meeting

Investors need to pay close attention to Mirati Therapeutics (MRTX) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Mirati Therapeutics (MRTX) Stock?

Blueprint Medicines

Eli Lilly

Two presentations at the World Conference on Lung Cancer will make a big difference for at least four different drugmakers.

News for Mirati Therapeutics Stock (MRTX)